# LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus

> **NCT00349986** · PHASE4 · TERMINATED · sponsor: **Sanofi** · enrollment: 4 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insuline glargine

## Key facts

- **NCT ID:** NCT00349986
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2007-06
- **Final completion:** —
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** prematurely terminated due to loss of interest
- **Last updated:** 2009-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00349986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00349986, "LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00349986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*